Related Experiment Video

Updated: May 16, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Long-term outcomes after switching from baricitinib 4 mg to upadacitinib 30 mg in atopic dermatitis: A 144-week

Teppei Hagino¹, Hidehisa Saeki², Eita Fujimoto³

¹Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.

Journal of the American Academy of Dermatology

|May 14, 2026

Abstract

No abstract available in PubMed .

Keywords:

Janus kinase atopic dermatitis baricitinib switch upadacitinib

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Effects of Switching From Deucravacitinib to Tildrakizumab in Psoriasis: A 28-Week Real-World Study.

Journal of psoriasis and psoriatic arthritis·2026

Routine blood biomarkers associated with clinical response to tralokinumab in patients with atopic dermatitis: a 48-week real-world study in Japan.

European journal of dermatology : EJD·2026

Real-World Effectiveness of Tildrakizumab in Japanese Patients With Psoriasis: Analyses Stratified by Prior Systemic Therapy, Maintenance of Early Responses, and Achievement of Delayed Responses.

The Journal of dermatology·2026

Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years).

European journal of dermatology : EJD·2026

48-Week Real-World Outcomes of Lebrikizumab Treatment for Atopic Dermatitis: Systemic Therapy-Naive Versus -Experienced Patients.

American journal of clinical dermatology·2026

Seventy-Two-Week Real-World Outcomes of Tralokinumab Treatment for Moderate-To-Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity.

The Journal of dermatology·2026

See all related articles